Menu

External Publications

Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

Posted May 6, 2022
Citation:  Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J,… Read More

Tumor necrosis factor alpha neutralization attenuates immune checkpoint inhibitor- induced activation of intermediate monocytes in synovial fuid mononuclear cells from patients with infammatory arthritis

Posted February 16, 2022
Citation: Sørensen AS, Andersen MN, Juul-Madsen K, Broksø AD, Skejø C, Schmidt H, Vorup-Jensen T, Kragstrup TW. Tumor necrosis factor alpha neutralization attenuates immune checkpoint… Read More

Predictors of rheumatic immune-related adverse events and de novo inflammatory arthritis after immune checkpoint inhibitor treatment for cancer

Posted October 21, 2021

Case-control study identifying predictors of rheumatic toxicities and ICI-inflammatory arthritis. Read More

TNF in the era of immune checkpoint inhibitors: friend or foe?

Posted July 9, 2021

Review of clinical and preclinical studies that address the relationship between TNF, TNF inhibition and cancer. Read More

Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease

Posted January 21, 2021

Melanoma patients with preexisting autoimmune disease have similar efficacy and toxicity rates from immune checkpoint inhibition: Netherlands’ experience. Read More

Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation

Posted January 20, 2021

Immune checkpoint inhibitor-induced inflammatory arthritis….. not as transient as you may think! Read More